The Global Health Body Issues Alert Over Critical Lack of Obesity Injections

Fewer than 10% of patients eligible to benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it issues its initial recommendations on the drugs.

With over a billion individuals worldwide now living with obesity, it is advocating for more widespread and fairer availability to this class of drugs.

Based on forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.

"The latest guidance acknowledges that obesity is a chronic disease that can be addressed with thorough and continuous care," said its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and logistical bottlenecks are significant hurdles to widespread availability to the injections that can aid individuals in losing substantial weight, says the organization.

Skinny Jab Scarcity

Even in the current most favorable scenario, the production of GLP-1 therapies might only reach about 100 million people – under 10% of eligible patients, per the WHO.

The guideline urges governments and firms to increase access, via measures including licensing agreements.

A patent on a key compound – the primary component of a leading brand – is set to lapse in multiple nations in 2026.

The Way Obesity Injections Operate

The injections replicate a natural hormone to slow digestion, reduce hunger and enhance the sense of being full so individuals reduce food intake.

People commonly begin shedding pounds after several weeks of beginning the weekly injections.

Research points to patients may put most of the weight back on within a year of halting the drug, when their usual appetite resume.

Being carrying excess weight raises your likelihood for contracting diseases, including diabetes, heart disease, brain attack, and some malignancies.

Excess weight affects people in all nations and was associated with 3.7 million deaths worldwide in 2024, according to the WHO.